The International Vaccine Institute (IVI) is an independent international organization originally established at the initiative of the United Nations Development Programme in 1997. Its mission is to discover, develop, and deliver safe, effective, and affordable vaccines—empowering vaccine equity, impact, and sustainability globally. IVI’s current portfolio includes vaccines in multiple stages of pre-clinical and clinical development targeting infectious diseases that significantly impact low- and middle-income countries, including cholera, typhoid fever, chikungunya, shigellosis, salmonellosis, schistosomiasis, hepatitis E, HPV- and group A strep-related diseases, and COVID-19. IVI developed the world’s first low-cost oral cholera vaccine and a new-generation typhoid conjugate vaccine, both pre-qualified by the World Health Organization (WHO). IVI is headquartered in Seoul, Republic of Korea with a Europe Regional Office in Sweden, an Africa Regional Office in Rwanda, a Country Office in Austria, and a Country and Project Office in Kenya. IVI additionally co-founded the Hong Kong Jockey Club Global Health Institute in Hong Kong and hosts Collaborating Centers in Bhutan, Burkina Faso, Ghana, Ethiopia, and Madagascar. 42 countries and the WHO are members of IVI, and the governments of the Republic of Korea, Sweden, India, Finland, Austria, and Thailand provide state funding. For more information, please visit https://www.ivi.int.
解鎖市場時間軸與訊號動態
過去 90 日內有 2 個訊號。
此公司進入各市場的次序 — 由最舊至最新
DigitalOcean · 新加坡
新橋生物任命Srishti Gupta為首席執行官
註冊以查看完整訊號動態
International Vaccine Institute (IVI) 的國際擴張與競爭對手的比較
長條顯示所比較各公司之間的相對規模。
5 項指標| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
International Vaccine Institute (IVI)你 | 1 | 1 | -100% | 2 | 12 |
過去 90 日內開放了 16 個職位。
Seoul, South Korea · 3星期前
Associate Researcher (DSI_Data Management Department)
Seoul, South Korea · 上個月
Consultant (Policy & Economic Research Department)
Seoul, South Korea · 上個月
Financial Accounting & Reporting Manager (Accounting & Finance Department)
整個技術架構共偵測到 5 項技術。
無進行中的廣告活動
註冊以追蹤此公司,並在發生變化時第一時間獲得提醒。
過去 90 日內有 3 則提及。
GC綠十字醫療基金會透過韓國國際保健醫療基金會的獎學金計劃,為來自加納、越南、埃及等8個國家的感染病專家進行診斷檢測和感染應對系統培訓。
SK生物科學將領導蓋茨基金會資助的ROTOR項目,與PATH和Slalom開發AI平台,優化疫苗臨床開發決策,初期專注於低收入國家的輪狀病毒疫苗。
新橋生物任命Srishti Gupta博士為首席執行官,自2026年7月1日起生效,接替傅希湧博士。Gupta擁有超過20年領導經驗,將推進Givastomig和VIS-101邁向註冊階段。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 International Vaccine Institute (IVI) 業務、市場及增長訊號的快速解答。